Athena

About Athena

Athena Pharmaceutiques, SAS is development, manufacturing and licensing out company for Oral Solid dosage forms. For a decade now, Athena has been dedicated to developing lifecycle products and has developed a broad range of technology platforms for oral delivery with a special focus on modified release formulation. Using these technologies Athena has developed a wide range of products in various ...

  • IN
  • 2015
    On CPHI since
  • 500 - 999
    Employees
Company types
Manufacturer/Innovator
Primary activities
Contract Manufacturer
Excipients Manufacturer
Finished Formulation products Distributor/Buyer
Ingredients Distributor/Buyer
Contact info
  • STAR HUB Tower II,, 6th Floor, 602, Sahar, Andheri (East), 400059, Mumbai, Maharashtra, India

Products from Athena (3)

  • DONEPEZIL 5/10 mg ORO DISPERSIBLE TABLET

    Product DONEPEZIL 5/10 mg ORO DISPERSIBLE TABLET

    UNIQUE SELLING POINT:
    • Donepezil Oro-Dispersible Tablet is pleasant and convenient as a tablet that melts in the mouth and can be administered anytime anywhere with or without water. • Unique technology of Athena is an ideal choice for patients with Alzheimer’s disease(AD). • Significant imp...
  • DOMPERIDONE 10 mg ORO-DISPERSIBLE TABLET

    Product DOMPERIDONE 10 mg ORO-DISPERSIBLE TABLET

    UNIQUE SELLING POINT: • Firstline treatment of nausea and vomiting acting with lower potential to induce dystonic, extrapyramidal symptoms or galactorrhoea. • Orodispersible tablet formulation facilitating water-free intake by oral route in patients suffering from nausea and vomiting or who have difficult...
  • FENOFIBRATE 67/200/267 MG CAPSULE

    Product FENOFIBRATE 67/200/267 MG CAPSULE

    UNIQUE SELLING POINT:

    • Micronized formulation results improving patient’s compliance, daily dose reduction whilst ensuring an optimal drug efficacy. • Fenofibrate is a third generation fibric acid practically insoluble in water, making it challenging to consistently achieve therapeutic le...

Athena Resources (2)

  • News Inauguration of new R&D facility in Mumbai, India by Mr. Jean-Marc Séré-Charlet, Consul General of France- Mumbai

    Inauguration of new R&D facility in Mumbai, India by Mr. Jean-Marc Séré-Charlet, Consul General of France- Mumbai
  • Brochure LEAD DOSSIERS FOR L IC ENS ING

    CARDIO AND METABOLISM

    •Bisoprolol Aspirin 5 -10/75-100 mg Capsule - EU

    • Fenofibrate 160/200/267 mg Tablet & Capsule - EU

    PAIN

    •Paracetamol Tramado l 325/37.5 mg Table t & ODT - EU/ Brazil RESPIRATORY • Levocetirizin e 5 mg ODT - EU/ RUSSIA / Brazil

    CENTRAL NERVOUSSYSTEM

    •Etifoxine 50 mg Capsule - EU

    • Ondansetro n HCL/Base 4,8 mg ODT - EU/Canada/Brazil

    • Zolpidem 5,10 mg ODT & SL - Canada/Brazil/UE

    GASTRO INTESTINAL

    • Esomeprazol e 20, 40 mg Capsul e -EU

    • Mesalazine 1 g, 2 g Sache t - EU

    • Racecadotril 10, 30 mg Taste Masked Sachet –

     

    EU UROLOGY / GYNECOLOGY

    •Secnidazol e 2 g Taste Maske d pellets Sache t –EU

    • Metronidazole 500 mg Tablet - EU